Caligan Partners’s Agios Pharmaceuticals AGIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $35.6M | Buy |
1,071,258
+369,978
| +53% | +$12.3M | 6.85% | 4 |
|
|
2025
Q1 | $20.5M | Buy |
701,280
+75,000
| +12% | +$2.2M | 4.29% | 9 |
|
|
2024
Q4 | $20.6M | Buy |
626,280
+46,563
| +8% | +$1.53M | 5.21% | 7 |
|
|
2024
Q3 | $25.8M | Buy |
579,717
+65,006
| +13% | +$2.89M | 8.16% | 6 |
|
|
2024
Q2 | $22.2M | Buy |
514,711
+30,000
| +6% | +$1.29M | 5.19% | 8 |
|
|
2024
Q1 | $14.2M | Buy |
484,711
+42,878
| +10% | +$1.25M | 3.75% | 8 |
|
|
2023
Q4 | $9.84M | Buy |
441,833
+437,000
| +9,042% | +$9.73M | 3.32% | 7 |
|
|
2023
Q3 | $120K | Hold |
4,833
| – | – | 0.05% | 12 |
|
|
2023
Q2 | $137K | Buy |
4,833
+500
| +12% | +$14.2K | 0.08% | 12 |
|
|
2023
Q1 | $99.5K | Hold |
4,333
| – | – | 0.07% | 11 |
|
|
2022
Q4 | $122K | Buy |
+4,333
| New | +$122K | 0.1% | 11 |
|